Webinar on-demand

Opening Session

Welcome by Chairs

P. Lampertico and H. Wedemeyer

Session 1 - Virology and Pathogenesis

The HDV virus: the challenge

S. Urban

Pathogenesis of HDV: new insights

J. Lucifora

Immunology of HDV in untreated and treated patients

H. Kefalakes

Session 2 - Epidemiology and Diagnosis

Epidemiology of HDV: from low to high endemic countries

S. Hamid

Epidemiology of HDV in North America: a forgotten disease?

N. Reau

Diagnosis of HDV: clinical virology and new HBV biomarkers

M. Brunetto

Keynote Lecture

From HDV discovery to perspectives of cure

M. Rizzetto

Session 3 - Diagnosis and Natural History

Non-invasive markers of fibrosis in CHD: pros and cons

L. Castera

Natural history of untreated HDV patients: always a progressive disease?

S. Aleman

Endpoints of HDV therapy

M. Buti

Session 4 - Antiviral Treatment I

Peginterferon therapy: effectiveness, predictors, and long-term outcomes

T. Asselah

Bulevirtide with or without peginterferon alfa: clinical trials

H. Wedemeyer

Bulevirtide with or without peginterferon alfa: real-world studies

P. Lampertico

Session 5 - Antiviral Treatment II

Lonafarnib with or without peginterferon alpha/lambda

C. Yurdaydin

Anti-HBV drugs targeting HBsAg

F. Zoulim

Session 6 - Round Table Discussion

Hot topics in HDV management.
Academia, Pharma and Diagnostics representatives

For Academia: S. Aleman, V. de Lédinghen, N. Reau, F. Zoulim

For Pharma and Diagnostics: M. Biermer, I. Choong, G. Cloherty, J.F. Flaherty, C. Hwang, A. Reinhardt, C. Simon

Closing remarks

P. Lampertico and H. Wedemeyer